PuraPharm Corporation Limited, an investment holding company, researches, develops, produces, and sells concentrated Chinese medicine granule (CCMG) and Chinese healthcare products in Hong Kong, Mailand China, and internationally. More Details
Undervalued with mediocre balance sheet.
Share Price & News
How has PuraPharm's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 1498 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: 1498's weekly volatility (6%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: 1498 underperformed the Hong Kong Pharmaceuticals industry which returned 21.2% over the past year.
Return vs Market: 1498 underperformed the Hong Kong Market which returned 28.6% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is PuraPharm's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StPuraPharm's (HKG:1498) Profits Appear To Have Quality Issues
3 months ago | Simply Wall StHow Much Is PuraPharm Corporation Limited (HKG:1498) Paying Its CEO?
5 months ago | Simply Wall StHealth Check: How Prudently Does PuraPharm (HKG:1498) Use Debt?
Is PuraPharm undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 1498 (HK$0.7) is trading below our estimate of fair value (HK$1.71)
Significantly Below Fair Value: 1498 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 1498 is good value based on its PE Ratio (8.2x) compared to the HK Pharmaceuticals industry average (12x).
PE vs Market: 1498 is good value based on its PE Ratio (8.2x) compared to the Hong Kong market (11.7x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 1498's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 1498 is good value based on its PB Ratio (0.5x) compared to the HK Pharmaceuticals industry average (1.3x).
How is PuraPharm forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as PuraPharm has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has PuraPharm performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 1498 has a large one-off gain of HK$73.0M impacting its December 31 2020 financial results.
Growing Profit Margin: 1498 became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: 1498 has become profitable over the past 5 years, growing earnings by -64.4% per year.
Accelerating Growth: 1498 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 1498 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.7%).
Return on Equity
High ROE: 1498's Return on Equity (6.2%) is considered low.
How is PuraPharm's financial position?
Financial Position Analysis
Short Term Liabilities: 1498's short term assets (HK$607.7M) exceed its short term liabilities (HK$591.9M).
Long Term Liabilities: 1498's short term assets (HK$607.7M) exceed its long term liabilities (HK$271.0M).
Debt to Equity History and Analysis
Debt Level: 1498's debt to equity ratio (89.6%) is considered high.
Reducing Debt: 1498's debt to equity ratio has increased from 27.3% to 89.6% over the past 5 years.
Debt Coverage: 1498's debt is well covered by operating cash flow (26.2%).
Interest Coverage: Insufficient data to determine if 1498's interest payments on its debt are well covered by EBIT.
What is PuraPharm current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 1498's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 1498's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 1498's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 1498's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: 1498 is not paying a notable dividend for the Hong Kong market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 1498's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Abraham Chan (59 yo)
Mr. Yu Ling Chan, also known as Abraham, BASc C.Eng. MIStruct E. P.Eng., has been the Chief Executive Officer and Chairman of PuraPharm Corporation Limited. Mr. Chan has been a Director at PuraPharm Corpor...
CEO Compensation Analysis
Compensation vs Market: Abraham's total compensation ($USD373.08K) is above average for companies of similar size in the Hong Kong market ($USD230.70K).
Compensation vs Earnings: Abraham's compensation has been consistent with company performance over the past year.
Experienced Management: 1498's management team is considered experienced (2.6 years average tenure).
Experienced Board: 1498's board of directors are considered experienced (5.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: 1498 insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
PuraPharm Corporation Limited's company bio, employee growth, exchange listings and data sources
- Name: PuraPharm Corporation Limited
- Ticker: 1498
- Exchange: SEHK
- Founded: 1998
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: HK$275.084m
- Shares outstanding: 392.98m
- Website: https://www.purapharm.com
Number of Employees
- PuraPharm Corporation Limited
- Jardine House
- Suite 4002
- Hong Kong
PuraPharm Corporation Limited, an investment holding company, researches, develops, produces, and sells concentrated Chinese medicine granule (CCMG) and Chinese healthcare products in Hong Kong, Mailand Ch...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/04/11 10:21|
|End of Day Share Price||2021/04/09 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.